Novel modified exendins and exendin agonist analogs having an exendin or exendin
agonist analog linked to one or more polyethylene glycol polymers, for example,
and related formulations and dosages and methods of administration thereof are
provided. These modified exendins and exendin agonist analogs, compositions and
methods are useful in treating diabetes and conditions that would be benefited
by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting
food intake.
